Navigation Links
Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
Date:9/30/2008

m early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
2. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
3. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
5. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
6. Micromet to Present at Two Upcoming Investor Conferences
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
9. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
10. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
(Date:7/10/2014)...   Ceres, Inc . (Nasdaq: CERE ... financial results for the three months ended May 31, ... Ceres reported that the company and its customers ... season in Brazil, which concluded in June, despite dry ... areas for part of the growing season. Yields of ...
(Date:7/10/2014)... D.C., June 17, 2014 Using microscopic polymer ... specific gases, researchers at MIT,s Quantum Photonics Laboratory ... levels in the parts-per-billion range. Optical sensors are ... their high signal-to-noise ratio, compact, lightweight nature, and ... gas sensors had been developed before, the MIT ...
(Date:7/10/2014)... the fractional quantum Hall effect in bilayer graphene and ... tuned by an electric field. , The fractional ... to thin sheets are exposed to large magnetic fields, ... of individual electrons behave as a single system. However, ... established, many details of this collective behavior remain not ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Swell new sensors 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
... Stockholders Approve Board Authority to Implement Reverse Stock Split and ... of Total Shares and Authorized Shares, NEW HAVEN, Conn., ... that a Special Meeting of,Stockholders was held at the Omni ... At the meeting, shareholders voted to approve amendments to the,Company,s ...
... - For Full Year 2007, Strong Operating Earnings and Tax Benefits Drive ... and Product Sales Both Grow 14% -, - In 2008, Gen-Probe Expects ... Driving Anticipated EPS of ... GPRO ) today reported strong financial results for the fourth,quarter and ...
... DENVER, Feb. 13 Rocky Mountain Biosystems, ... announced receipt of a,grant award of approximately ... of Allergy and Infectious Diseases at the ... Self-Administered Vaccination Electromechanical,(SAVE) technology for influenza vaccination. ...
Cached Biology Technology:Vion Pharmaceuticals Holds Special Meeting of Stockholders 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 3Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 2Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 3Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 4Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 5Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 6Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 7Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 8Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 9Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 10Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 11Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 12Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 13Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 14Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 15Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 16NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza 2
(Date:7/11/2014)... Institute of Standards and Technology (NIST) need a ... they often prove that necessity is truly the ... for M. Lorna De Leoz and Stephen Stein, ... glycomics. Glycomics is the study of the abundant, ... to proteins and lipids and influence cellular processes, ...
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... and the Manchester Metropolitan University have carried out the ... amber more than 30 millions years ago. , The ... the Dominican (Caribbean) regions has revealed new insights into ... period. , It is the first time ancient spiders ...
... at the National Institute of Allergy and Infectious Disease ... (NIH), have identified a critical human cell surface molecule ... virus that causes Kaposi's sarcoma and certain forms of ... HIV/AIDS, and it typically manifests as multiple purple-hued skin ...
... the amino acid supplement L-arginine following a heart attack ... may be associated with an increased risk of death, ... of JAMA. , L-arginine is a widely available dietary ... with hypertension, angina, heart failure and sexual dysfunction, according ...
Cached Biology News:Amber reveals ecology of 30 million year old spiders 2Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor 2Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor 3Little known DNA repair enzyme may be a tumor suppressor gene 2
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Biology Products: